Hydroxyapatite Nanoparticles Facilitate Osteoblast Differentiation and Bone Formation Within Sagittal Suture During Expansion in Rats [Corrigendum]

Liang W, Ding P, Li G, Lu E, Zhao Z. *Drug Des Devel Ther.* 2021;15:905–917.

Figure 1D and E on page 909 is incorrect. The correct Figure 1 is shown below.

Page 908, Animal Model section, line 3 from the bottom, the text “100 µg/mL” should read “25 µg/mL”.

Figure 1 Characterization and differentiation of suture-derived stem cells (SuSCs). **(A)** Schematic illustration of holes made on the parietal bone to place the expansion appliance and absorbable collagen sponge. **(B)** Oil red staining indicated lipid restoration in SuSCs after cultured in lipid-forming medium for 21 days; white arrows indicate oil drop scale bar; 200 µm. **(C)** Alizarin red S staining of SuSCs cultured in osteogenic medium at day 14; white arrows indicate calcium nodules scale bar; 100 µm. **(D)** Flow cytometry analysis shows that SuSCs are expressing markers CD11b/c (75.00%), CD29 (19.94%) and CD90 (81.89%), but **(E)** not expressing markers CD34 (0.30%), CD44 (0.25%), CD45 (0.29%) and CD73 (0.29%).

Page 910, Characteristics of Synthesized nHAP section, second to last sentence, the text “Moreover, based on the XRD pattern, we identified that the crystallinity degree of nHAP was $76 \pm 3.6\%$ ” should read “Moreover, based on the XRD pattern, we identified that the crystallinity degree of nHAP was $76 \pm 3.6\%$ (Figure 2C)”.

Page 910, Characterization of Isolated SuSCs section, second sentence, the text “Flow cytometric characterization analysis showed that the SuSCs were homogenously positive (Figure 1D) for CD90 (94.54%), CD29 (75.12%)

and CD11b/c (90.81%) and negative (Figure 1E) for CD34 (1.56%), CD44 (1.35%), CD45 (1.00%) and CD73 (9.32%)” should read “Flow cytometric characterization analysis showed that the SuSCs were homogenously positive (Figure 1D) for CD90 (81.89%), CD29 (19.94%) and CD11b/c (75.00%) and negative (Figure 1E) for CD34 (0.30%), CD44 (0.25%), CD45 (0.29%) and CD73 (0.29%)”.

The authors apologize for these errors and advise they do not affect the conclusion of the paper.

Drug Design, Development and Therapy

Dovepress

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also

been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>

<https://doi.org/10.2147/DDDT.S331356>